T cell infiltration is known to impact tumor growth and is associated with cancer patient survival.
INTRODUCTION
T cell infiltration is a known predictor of patient survival in several cancers, including colorectal and ovarian cancers, non small cell lung carcinomas, and melanomas (1) (2) (3) (4) (5) . T cell adoptive therapies represent an attractive approach to treating cancers, and have yielded some promising results in melanoma even though complete clinical responses are only observed in a minority of patients (6) . Recently the Food and Drug Administration approved the first therapeutic cancer vaccine (sipuleucel-T) for advanced prostate cancer (7) . However, even when cancer vaccines induce immune responses in the majority of patients, only a few benefit from the treatment (8) (9) . This continuing growth of tumors in the presence of functional anti-tumor immune responses, whether spontaneous or induced, is the most disturbing paradox of tumor immunology (10) . The so far limited success of therapeutic cancer vaccines is largely due to our incomplete understanding of the mechanisms preventing the action of T cells locally. T cell recruitment to the tumor is one of the potential rate-limiting steps in immunotherapy, and thus, intra-tumoral chemokines are likely to have a major impact (11) (12) . Gene expression profiling studies have shown that intra-tumoral expression of chemokines indeed correlate with T cell infiltration (13) . Therefore, identifying drugs that favor T cell trafficking to the tumors is essential to improve cancer vaccines.
Chemotherapy acts, in part, by direct induction of apoptosis in cancer cells. In addition, selected chemotherapies may promote immunogenic cell death, which stimulates the anti-tumor immune response (14) . Chemotherapy can also induce stress signals leading to increased susceptibility of cancer cells to immune attack (15) . In melanoma, mixed responses to chemotherapy are frequently observed (16) . We therefore sought to understand the signals responsible for T cell trafficking to cutaneous tumors in melanoma and to determine whether they are altered by chemotherapy.
We recently described the RETAAD model of melanoma (17) . RETAAD mice develop spontaneous uveal melanomas which metastasize to the skin and visceral organs (18) . Tumorbearing animals mount a strong anti-tumor T cell response, but while this response controls the outgrowth of visceral metastases, they have no effect on cutaneous tumors. We suspected that differential T cell trafficking might explain this apparent paradox. Using global transcriptome analysis, we also analyzed cutaneous metastases resected from melanoma patients before and after chemotherapy, and found increased T cell infiltration into the chemotherapy-sensitive tumors (19) .
The aim of the present study is to identify molecular cues controlling T cell infiltration into cutaneous tumors and to find treatments promoting T cell infiltration. We address this question in the RETAAD model and in melanoma patients treated with chemotherapy. Our findings indicate that chemotherapy works, in part, through the induction of chemokine expression in cancer cells and the subsequent recruitment of T cells into the tumors.
MATERIALS AND METHODS

Cell lines and antibodies
The B16-F10 (Cat Nr CRL-6475) and HTB-71 cell lines were from ATCC. The Melan-ret cell line was previously described (20) . The four human melanoma cell lines (M88, M102, M131, and M134) were kindly provided by J-B Latouche and P. Musette. The anti-CXCR3 antibody was produced by immunizing CXCR3-deficient mice with L1.2 cells expressing mouse CXCR3, as described previously (21) .
Mice and patients
Animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of the Biological Resource Center, A*STAR, Singapore. Human tumor samples, patient demographics and clinical characteristics can be found in (19) .
Gene expression analysis
Expression of immune genes relative to Gapdh (for mouse) and ACTB (for human) was measured by quantitative real-time PCR (qRT-PCR) as previously described (18) . ΔCt and primer efficiency were used to calculate the relative expression.
Expression of chemokine and chemokine receptor genes was determined by qRT-PCR with the Mouse Inflammatory Cytokines and Receptors RT 2 profiler PCR array system (SABiosciences) and data analysis was performed according to the manufacturer's instructions.
Immunofluorescence
Formalin-fixed paraffin-embedded sections (5μm) were immunolabeled for CD3 (Acris SM1754P; 1:50) using the protocol previously described (18) . 
Flow cytometry analyses
Single cell suspensions were obtained by digestion with Collagenase A (1mg/ml) and DNase I (0.1mg/ml) (Roche) in RPMI for 20min. After red blood cell lysis, Fc receptors were blocked with anti-mouse CD16/CD32 for 30min before incubation with antigen-specific antibodies at 1:50 dilution for 20min. All antibodies were from Biolegend, except those specific for CCR1, CCR2, and CCR5 which were from R&D Systems.
Construction of expression plasmids
CCL5-and CXCL9-expressing plasmids are described in Supplementary Figure 3 . Briefly, RNA from LPS-activated macrophages was reverse transcribed, PCR amplified using specific primers for Ccl5 (5'primer TACCGAGCTCGGATCCATGAAGATCTCTGCAGCTG; 3'primer AAAC GGGCCCTCTAGAGCAGGGTCAGAATCAAGAAACC), and Cxcl9 (5'primer TACCGAGCT CGGATCCGCCACCATGAAGTCCGCTGTTC; 3'primer GCCCTCTAGACTCGAGCTCTTA TGTAGTCTTCCTTG). PCR products were cloned into pcDNA3.1 Hygro(+) (Invitrogen) at BamHI/XbaI sites (for Ccl5) and at BamHI/XhoI sites (for Cxcl9). Chemokine-expressing and control plasmid preparations were tested for endotoxin using Limulus amebocyte lysate assay (Lonza, 50-647U).
In vivo experiments
RETAAD T cell migration to skin tumors
Tumor-bearing RETAAD mice (aged between 30-50 weeks) were injected subcutaneously in the right flank with 2x10 5 B16-F10luc cells (Xenogen, Alameda, CA). Mice were euthanized when the tumor diameter reached 1cm. The B16 transplanted skin tumor and 1 or 2 RETAAD skin 7 tumors were collected from the same mouse. T cell infiltration into tumors was measured by flow cytometry.
In vivo transfection of cutaneous tumors
Tumor-bearing RETAAD mice (30-50 weeks) were used. For each mouse, 2 to 7 cutaneous tumors were transfected with 5ug of pcDNA3.1(+)-CCL5 or -CXCL9 or empty plasmid using in vivo JetPEI transfecting reagent (Polyplus Transfection). Three injections were performed on alternate days for 5 days. On day 6, the mice were euthanized and the tumors excised, weighed and divided into two parts. One part was used for intra-tumoral mRNA expression of Ccl5, Cxcl9, Cxcl10, Ifng, Gzma, and Gzmb by qRT-PCR; the other was dissociated and analyzed for immune cell infiltration by flow cytometry. For Ccl5 and Cxcl9 co-injection studies, 2.5µg of pcDNA3.1(+)-CCL5, -CXCL9, empty plasmid or a combination of 5µg of pcDNA3.1(+)-CCL5
and -CXCL9 were injected into cutaneous RETAAD tumors using the protocol described above.
T cell infiltration and intra-tumoral chemokine expression were measured as previously described.
Chemotherapy and adoptive transfer
Rag1 -/-mice were injected subcutaneously with 10 6 Melan-ret cells. When tumors became palpable, mice were treated for 2 consecutive days with 2mg Temozolomide or vehicle (DMSO)
only. On the following day, mice were injected i.v. with 10 7 in vitro activated T cells purified from C57BL/6 with or without 2µg anti-CXCR3 antibody. T cell infiltration and intra-tumoral expression of chemokines were measured 24h after transfer.
Chemotherapeutic drug treatment and chemokine gene expression Human melanoma cells were seeded into 12-well plates (4x10 5 /well). 48h later, drugs were added at indicated concentrations. RNA extraction was performed as described previously, and the expression of CCL5, CXCL9 and CXCL10 was analyzed by qRT-PCR.
Multiplex analysis of chemokine/cytokine production by tumor cells
Concentrations of various cytokines/chemokines in the supernatant of drug-treated cells were analyzed using multiplex bead-based assays based on xMAP technology, combining both the 21-plex (MF0-005KMII) and 27-plex (M50-0KCAF0Y) kits from Biorad and according to the manufacturer's protocol.
Statistical analyses
Normalised gene expression data were log-transformed and initially compared using a manova multivariate analysis. This was followed by post-hoc testing using Student's t-test or ANOVA. Pvalues for multiple comparisons were adjusted using Bonferroni correction. Other parameters (tumor weight, tumor area, percentage of tumor-infiltrating cells) were compared using nonparametric tests (Mann-Whitney or Kruskal-Wallis). Patient survival was analyzed by the Kaplan-Meier method using log-rank (Mantel-Cox) test. Statistical analyses were performed using Graphpad or Bioconductor/R. 
RESULTS
Limited T cell infiltration of cutaneous tumors
In RETAAD mice, CD8 + T cells control the outgrowth of visceral metastases but have no effect Figure 1D ). Taken together these data demonstrate that both CD4 + and CD8 + T cells poorly infiltrate cutaneous tumors in RETAAD mice. This observation is likely to explain the lack of T cell control over cutaneous tumors.
T cells infiltrate exogenous skin tumors
To determine whether the poor infiltration of T cells into cutaneous tumors was due to an intrinsic defect in T cells from RETAAD mice or a feature of the tumors themselves, we compared autochthonous RETAAD and transplanted B16 cutaneous tumors. B16 cells were injected subcutaneously into tumor-bearing RETAAD mice. Fourteen days after injection, the transplanted B16 and autochthonous RETAAD tumors were excised and T cell infiltration was measured. As shown in Figure 2A , CD3 + , CD4 + and CD8 + T cells were respectively 11-fold, 9-fold and 11-fold more abundant in B16 than in RETAAD tumors (two-tailed Mann-Whitney, p<0.01).
These data show that T cells from RETAAD mice have the capacity to infiltrate cutaneous tumors. Therefore, the paucity of T cells in RETAAD cutaneous tumors is most likely due to the tumor environment being poorly permissive to T cell infiltration.
T cell infiltration of exogenous skin tumors correlates with high chemokine expression
Chemokines present in tumors are likely to play a major role in T cell recruitment. We therefore CXCR3 has only three known ligands: CXCL9, CXCL10 and CXCL11. Therefore, our data strongly suggest a role for CXCL9 and CXCL10 in T cell recruitment into cutaneous tumors.
Transfection of RETAAD skin tumors with Cxcl9 induces T cell infiltration
To directly demonstrate the role of CXCR3 ligands in T cell recruitment, we transfected established RETAAD autochthonous tumors with a plasmid encoding CXCL9. RETAAD mice bearing multiple cutaneous metastases (median weight=60mg) were selected for this experiment.
Three intra-tumoral injections were performed on alternate days. In each mouse, one or two tumors were injected with the CXCL9-encoding plasmid and one or two tumors were injected with a control plasmid. On day 6, tumors were excised, weighed and T cell infiltration was Taken together, these observations show that CXCL9 attracts effector T cells exhibiting type 1 polarization and cytotoxic potential.
Cxcl9 expression inhibits exogenous tumor growth in a T cell-dependent manner
We next investigated whether ectopic expression of Cxcl9 could control tumor growth in vivo. expression and a 3-fold increase in Cd3g expression ( Figure 3E ). When the same experiment was repeated in Rag1 -/-mice, there was no significant difference in the growth of Cxcl9-transfected and control tumors ( Figure 3F ). These data demonstrate that Cxcl9 expression inhibits tumor growth and that this inhibition is dependent on a lymphoid cell population.
CXCL9 synergizes with CCL5 to recruit T cells
Knowing that CXCL9 promotes T cell recruitment and that chemokines often act in concert, we then asked whether other chemokines expressed in RETAAD tumors were also involved in T cell infiltration. By comparing a set of 37 cutaneous or visceral tumors, we found that Ccl5 Figure 6B) . This increased infiltration of T cells in tumors co-injected with CCL5 and CXCL9 plasmids was not due to CCL5-mediated increase in CXCL9 production (data not shown). Conversely, T cells may undergo changes in chemokine receptor expression upon infiltration into the tumor. We therefore compared CCR5 expression on TIL (n=16) and blood lymphocytes (n=6). Interestingly, we detected a small but reproducible increase in the percentage of CCR5-expressing CD4 + and CD8 + (40% and 80% increase, respectively) in TIL compared to blood lymphocytes ( Figure 3H ).
Altogether, these data demonstrate a synergy between CXCL9 and CCL5 for T cell recruitment and suggest that CCR5 up-regulation in the tumor microenvironment may favor T cell retention in CCL5-expressing tumors.
Chemotherapy induces chemokine production in human melanoma cell lines
Chemotherapy is known to alter the transcriptome of cancer cells and has been reported to modify their profile of chemokine secretion (22) . We therefore tested three chemotherapeutic We therefore focused on temozolomide (which shares the same active metabolite as dacarbazine) and cisplatin for the rest of the study. Figure 4C shows the kinetics of CCL5, CXCL9 and CXCL10 induction in M102 cells following treatment with 100µg/ml temozolomide.
Transcription of
We confirmed that CCL5, CXCL9 and CXCL10 mRNA were translated into proteins by analyzing supernatants of M102 cells 72h after treatment with temozolomide (100µg/ml) or cisplatin (10µg/ml). Using ELISA and Luminex-based Bio-Plex suspension arrays, culture supernatants were tested for a variety of secreted proteins, including 28 cytokines, 7 additional chemokines and 10 angiogenic and growth factors. As shown in Figure 4D , temozolomide induced a more than 9-fold increase in the secretion of five chemokines (CCL2, CCL5, CXCL8, CXCL9 and CXCL10) and one chemokine-like factor (MIF), while cisplatin induced CXCL8, CXCL10 and MIF. Importantly, none of the other factors were significantly induced (Table 1) .
Altogether, these data demonstrate that three chemotherapeutic drugs commonly used for the treatment of human metastatic melanoma induce specific expression of chemokines involved in T cell attraction. 
Enhanced expression of CCL5, CXCL9 and CXCL10 after chemotherapy is associated with tumor control and superior survival of melanoma patients.
We previously showed increased T cell infiltration in chemotherapy-sensitive tumors of melanoma patients treated with dacarbazine (19) . In the previous study, we performed global transcriptome analysis of 33 cutaneous metastases resected before or after chemotherapy. We now re-analyzed these data, asking whether there were any chemokine whose expression correlated with T cell infiltration. Among all the genes coding for chemokines, CCL5, CXCL9
and CXCL10 were the most significantly correlated with CD3Z and CD8A expression, and among the most significantly correlated with CD4 ( Figure 6A ). We next compared CD4 and CD8A expression in three categories of tumor samples: those that expressed low levels of the three chemokines, those that expressed high levels of CCL5 or high levels of CXCR3 ligands, and those that expressed high levels of CCL5 and high levels of at least one CXCR3 ligand. This comparison revealed a clear synergy between CCL5 and CXCR3 ligands for T cell infiltration ( Figure 6B ). To determine whether chemotherapy had any impact on chemokine expression, we compared CCL5, CXCL9 and CXCL10 expression in tumors before and after therapy. As shown in Figure 6C , while dacarbazine did not induce any significant changes in chemotherapy-resistant tumors, i.e. progressing lesions, an increase in CCL5, CXCL9 and CXCL10 expression was observed after treatment in chemotherapy-sensitive tumors (one-tailed t-test, p=0.006, 0.017 and 0.041, respectively). CD4 and CD8A expression was also significantly increased in chemotherapy-sensitive tumors (p=0.0004 and 0.0009, respectively; Figure 6D ). Manova multivariate analysis showed that chemokines and T cell markers were significant predictors of Our study also reveals a striking synergism between CXCR3 ligands and CCL5 in attracting T cells into melanoma tumors of both humans and mice. At this stage, the exact mechanism accounting for this synergy is unclear since circulating T cells only express very low levels of CAN-11-1466 CCL5-receptors. In fact, less than 2% of CD8 + T cells in the RETAAD mice express CCL5
receptors. CCL5 transfection did not enhance CXCL9 expression in the tumor and transfection of CCL5 alone has no effect on T cell attraction. However we did observe an increased percentage of CD4 + and CD8 + T cells expressing CCR5 among the TIL, suggesting either that CCR5-expressing T cells are preferentially attracted into the tumor or that upon infiltration, T cells upregulate CCR5. We propose that intra-tumoral expression of CCL5 might facilitate the retention of CCR5-expressing T cells, thereby augmenting the percentage of CCR5 + TIL. We could not directly test this hypothesis in melanoma patients, but we did find that intra-tumoral expression of CXCR3 ligands and CCL5 in chemotherapy-treated tumors does lead to a synergistic increase in T cell infiltration.
The present study provides evidence for a novel mode of action of chemotherapeutic drugs. Table 1 Multiplex analysis of soluble factors secreted by M102 cell line after chemotherapeutic drug treatment. Human melanoma cell line M102 was cultured with temozolomide (100µg/ml) or cisplatin (10µg/ml) for 3 days. Supernatants were collected and the concentrations of various soluble factors were analyzed using xMAP multiplex technology. Data show the production of cytokines, chemokines, angiogenic and growth factors in pg/ml±SD from the supernatant of drug-treated cells compared to control cells. Results are representative of 3 independent samples analyzed. Secreted factors that are significantly upregulated after drug-treatment are indicated in bold. ND = Not Detected; NA = Not Available. Mann-Whiney U test, one-tailed. 
